FierceBiotech

FDA Approves NULOJIX® (belatacept)

For Prophylaxis of Organ Rejection in Adult Patients Receiving a Kidney Transplant in Combination with Basiliximab Induction, Mycophenolate Mofetil, and Corticosteroids Offers Comparable Overall ...
Monthly Prescribing Reference

Nulojix Approved for Renal Transplant Patients

Nulojix carries a Boxed Warning for an increased risk of developing post-transplant lymphoproliferative disorder (PTLD), a type of cancer in which white blood cells grow out of control after an organ ...
FierceBiotech

FDA Approves Nulojix for Kidney Transplant Patients

SILVER SPRING, Md., June 15, 2011 /PRNewswire-USNewswire/ --The U.S. Food and Drug Administration today approved Nulojix (belatacept) to prevent acute rejection in adult patients who have had a kidney ...
Monthly Prescribing Reference

SAFETY ALERT: REMS Required for Nulojix for Post-Transplant Lymphoproliferative Disorder and Progressive Multifocal Leukoencephalopathy Risk

Bristol-Myers Squibb has notified healthcare professionals that a Risk Evaluation and Mitigation Strategy (REMS) is required for Nulojix (belatacept) to ensure that the benefits of Nulojix outweigh ...
San Diego Union-Tribune

Bristol-Myers gets FDA OK on new transplant drug

TRENTON, N.J.TRENTON, N.J. — The first new type of drug in more than a decade for keeping transplanted kidneys functioning won approval from federal regulators on Wednesday. The Food and Drug ...
PharmaTimes

FDA approves B-MS’ Nulojix to prevent kidney rejection

Regulators in the USA have given the green light to Bristol-Myers Squibb’s Nulojix for kidney transplant patients. Regulators in the USA have given the green light to Bristol-Myers Squibb’s Nulojix ...
FiercePharma

New Data from Bristol-Myers Squibb on NULOJIX® (belatacept) to be Presented at the 2011 European Society for Organ T

PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE:BMY) today announced that new data on NULOJIX (belatacept) will be presented at the European Society for Organ Transplantation ...
The Financial

Bristol-Myers’ Nulojix beats cyclosporine in long-term study

The FINANCIAL — Bristol-Myers Squibb Company on May 6 announced results from a 7-year, long-term follow-up from a prospective, randomized Phase III trial (BENEFIT) in kidney transplant patients, which ...
Mena FN

Global Nulojix Market: Key Trends, Market Share, Growth Drivers, And Forecast For 2025-2034

LONDON, GREATER LONDON, UNITED KINGDOM, January 30, 2025 /EINPresswire / -- How has the nulojix market grown and what factors have contributed to this growth? The historic surge in the nulojix market ...
VietNamNet

FDA approves Nulojix for kidney transplant patients

The U.S. Food and Drug Administration (FDA) on Wednesday approved Nulojix to prevent acute rejection in adult patients who have had a kidney transplant. The drug is approved for use with other ...
Drug Store News

FDA approves Nulojix

SILVER SPRING, Md. — The Food and Drug Administration has approved a new drug for preventing organ rejection in kidney transplant patients, the agency said Wednesday. The FDA approved Bristol-Myers ...